You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Tony Fong is managing editor for 360Dx, GenomeWeb's news site on the in vitro diagnostics market.
In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity
The partners will use Namocell's single-cell dispensing tool and Takara's Smart-seq technology to isolate and characterize HepaTx's hepatocyte-like cells.
Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.
Winship's director of the cancer tissue and pathology shared resource said that some labs aren't leveraging molecular technologies due to reimbursement issues.
While molecular testing is now routine in cancer and women's health, for other disease areas, the technology may be overkill, Sundin said.
With recent and impending launches of POC MDx platforms, some industry observers believe the technology could replace some POC immunoassays in a few years.
The Singaporean molecular diagnostics firm, which went into judicial management in March, has new financial backing from a Chinese pharmaceutical firm.
Launched in April, the Japan Agency for Medical Research and Development is charged with streamlining that country's unwieldy funding process.
The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said.
The firm aims to inform consumers about genomics and genetic testing, and open up opportunities for more patients to be included in cancer drug trials.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.